Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Aethlon Medical Inc

Healthcare US AEMD

2.1USD
-0.11(4.98%)

Last update at 2026-06-03T20:21:00Z

Day Range

2.032.15
LowHigh

52 Week Range

1.3635.20
LowHigh

Fundamentals

  • Previous Close 2.21
  • Market Cap3.69M
  • Volume267704
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-7.00702M
  • Revenue TTM0.57M
  • Revenue Per Share TTM0.24
  • Gross Profit TTM 0.57M
  • Diluted EPS TTM-49.52

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Income before tax -13.38809M -12.20817M -12.02979M -10.42089M -7.89150M
Minority interest - - 0.00000M 0.00479M -0.13691M
Net income -13.38809M -12.20817M -143.17779M -10.41609M -7.84835M
Selling general administrative 9.34M 7.01M 12.47M 10.72M 8.55M
Selling and marketing expenses - 5.63M - - -
Gross profit -0.33956M -0.35906M -4442.97775M 0.29M 0.66M
Reconciled depreciation 0.34M 0.36M 0.24M 0.12M 0.04M
Ebit -13.37798M -12.63657M -11.89864M -10.54457M -7.92986M
Ebitda -13.03842M -12.27751M -11.75652M -10.42089M -7.88992M
Depreciation and amortization 0.34M 0.36M 0.14M 0.12M 0.04M
Non operating income net other - - - - -
Operating income -9.34136M -12.63657M -11.89864M -10.42089M -7.88992M
Other operating expenses 9.34M 12.64M 12.47M 10.72M 8.55M
Interest expense 0.01M - 131.15M -0.12369M 0.00158M
Tax provision - - - - -
Interest income 0.30M 0.43M 0.01M - -
Net interest income 0.29M 0.43M 0.01M - -0.00158M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.00000M 131.15M -0.00479M -0.04315M
Total revenue 0.00000M 0.00000M 0.57M 0.29M 0.66M
Total operating expenses 9.34M 12.64M 12.47M 10.72M 8.55M
Cost of revenue 0.34M 0.36M 4443.55M 4625.80M 3454.94M
Total other income expense net -4.04673M 0.43M -0.13115M 4.79M -0.00158M
Discontinued operations - - - - -
Net income from continuing ops -13.38809M -12.20817M -12.02979M -10.42089M -7.89150M
Net income applicable to common shares - - -12.02979M -10.41609M -7.88671M
Preferred stock and other adjustments - - - - -
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 7.36M 8.25M 17.51M 19.42M 10.67M
Intangible assets 0.00055M 0.00110M 0.00165M 0.00220M 0.06M
Earning assets - - - - -
Other current assets 0.45M 0.78M 0.56M 0.96M 341.08M
Total liab 2.24M 2.48M 2.44M 2.43M 1.38M
Total stockholder equity 5.12M 5.77M 15.06M 17.13M 9.43M
Deferred long term liab - - - - -
Other current liab 1.05M 0.76M 0.59M 0.85M 0.88M
Common stock 0.00259M 0.00263M 0.02M 0.02M 0.01M
Capital stock 0.00259M 0.00263M 0.02M 0.02M 0.01M
Retained earnings -167.95482M -154.56673M -142.36470M -130.32918M -119.91309M
Other liab - - - - -
Good will - - - - -
Other assets - 0.00000M 0.12M 0.12M 0.06M
Cash 5.50M 5.44M 14.53M 17.07M 9.86M
Cash and equivalents - - - - -
Total current liabilities 1.90M 1.83M 1.51M 1.82M 1.38M
Current deferred revenue - - 0.21M 0.34M 0.11M
Net debt -4.85151M -4.50166M -13.32391M -16.34301M -9.81903M
Short term debt 0.31M 0.29M 0.27M 0.13M 0.04M
Short long term debt - - - - -
Short long term debt total 0.65M 0.94M 1.21M 0.73M 0.04M
Other stockholder equity 173.09M 160.34M 163.55M 147.45M 129.33M
Property plant equipment - - 2.30M 1.14M 0.20M
Total current assets 5.95M 6.23M 15.09M 18.16M 10.35M
Long term investments - - - - -
Net tangible assets - - 15.06M 17.13M 9.37M
Short term investments - - - - -
Net receivables - - 0.00000M 0.13M 0.15M
Long term debt - - - - -
Inventory - - - - -340.73992M
Accounts payable 0.53M 0.78M 0.43M 0.50M 0.34M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -0.13691M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.01713M -0.00694M -6.14100M - -0.42493M
Additional paid in capital - - - - -
Common stock total equity - - - - 0.01M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -119.91309M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.03M 0.03M 0.12M 0.12M 0.06M
Deferred long term asset charges - - - - -
Non current assets total 1.41M 2.02M 2.42M 1.26M 0.32M
Capital lease obligations 0.65M 0.94M 1.21M 0.73M 0.04M
Long term debt total - - - - -
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Investments 0.00000M -0.25087M -0.94311M -0.34919M -0.05988M
Change to liabilities - - -0.51927M 0.33M 0.36M
Total cashflows from investing activities - -0.25087M -0.94311M -0.34919M -0.05988M
Net borrowings - - - - -
Total cash from financing activities 7.73M 1.29M 8.91M 17.37M 7.13M
Change to operating activities - - 0.46M -0.59947M -0.10466M
Net income -13.38809M -12.20817M -12.02979M -10.42089M -7.89150M
Change in cash 0.07M -9.09097M -2.53948M 7.25M 0.30M
Begin period cash flow 5.53M 14.62M 17.16M 9.91M 9.60M
End period cash flow 5.60M 5.53M 14.62M 17.16M 9.91M
Total cash from operating activities -7.64553M -10.12981M -10.50513M -9.76716M -6.76494M
Issuance of capital stock 3.54M 1.32M 8.93M 17.46M 7.26M
Depreciation 0.34M 0.36M 0.24M 0.12M 0.04M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - 0.46M - -0.10466M
Change to account receivables - 0.00000M 0.13M 0.02M 0.06M
Sale purchase of stock - - - - 7.26M
Other cashflows from financing activities 4.19M -0.03478M -0.01249M -0.08812M -0.13253M
Change to netincome - - 1.22M 0.78M 0.77M
Capital expenditures 0.00000M 0.25M 0.94M 0.35M 0.06M
Change receivables - - - - 0.06M
Cash flows other operating - - - - -0.11148M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - 0.30M
Change in working capital 0.09M 0.48M 0.07M -0.25111M 0.31M
Stock based compensation 0.42M 1.22M 1.05M 0.75M 0.78M
Other non cash items 4.89M 0.02M -46.59547M 0.03M -0.00249M
Free cash flow -7.64553M -10.38068M -11.44824M -10.11635M -6.82482M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AEMD
Aethlon Medical Inc		 -0.11 4.98% 2.10 - 0.21 2.37 0.54 18.80 51.98
ABT
Abbott Laboratories		 0.02 0.02% 86.99 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 1.70 0.58% 295.00 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 4.20 5.69% 77.95 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 0.01 0.02% 47.69 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices to treat cancer and viral infections in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended for applications in cancer, and life-threatening viral infections, and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California.

Aethlon Medical Inc

11555 Sorrento Valley Road, San Diego, CA, United States, 92121

Key Executives

Name Title Year Born
Dr. Charles J. Fisher Jr., M.D. CEO, Director & Member of Extracorporeal Therapy Advisory Board 1947
Mr. Steven P. Larosa M.D. Chief Medical Officer & Acting Chief Scientific Officer 1967
Mr. Guy F. Cipriani BS (Eng.), MBA Sr. VP, Chief Bus. Officer & Director 1970
Mr. James B. Frakes M.B.A. CFO, Sr. VP of Fin. & Sec. 1957
Mr. Sunil Sawhney Head of Clinical Studies NA
Dr. Richard H. Tullis Ph.D. Consultant 1945
Mr. Guy F. Cipriani BS (Eng.), MBA Chief Operating Officer 1971
Dr. Steven P. LaRosa M.D. Chief Medical Officer 1967
Mr. James B. Frakes M.B.A. Interim CEO, CFO, Secretary & Director 1957
Dr. Lee D. Arnold Ph.D. Chief Scientific Officer 1960

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions